The effect of atorvastatin on markers of bone turnover in patients with type 2 diabetes.
作者： G.D. Braatvedt , W. Bagg , G. Gamble , J. Davidson , I.R. Reid
DOI: 10.1016/J.BONE.2004.05.001
关键词: Osteocalcin 、 Type 2 diabetes 、 Bone remodeling 、 Internal medicine 、 Atorvastatin 、 Alkaline phosphatase 、 Bone density 、 Medicine 、 Endocrinology 、 Placebo 、 Statin
摘要: Abstract Retrospective and uncontrolled studies suggest that the lipid-lowering statin class of drugs has either no or beneficial effects on bone density may reduce fracture risk. We have examined atorvastatin serum plasma markers turnover in 25 patients (age 56 ± 8 years) with type 2 diabetes (duration: 4.7 5.0 years, 16 female, insulin-treated, 4 diet alone, 19 oral hypoglycemic agents) baseline hypercholesterolemia (cholesterol 6.6 0.8 mmol/l) a double-blind, placebo-controlled, crossover study 12 weeks placebo/40 mg an 8-week wash-out period. Atorvastatin resulted fall total cholesterol 2.3 0.9 mmol/l. There were active placebo therapy alkaline phosphatase, bone-specific osteocalcin, beta C-telopeptide 1 collagen (β-CTX). conclude (40 mg/day) significant effect man.
elsevier.com
sci-hub.se 参考文章(28)
Salim Yusuf, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary The Lancet. ,vol. 360, pp. 7- 22 ,(2002)
Masafumi Kuzuya, Yusuke Suzuki, Toshinobu Asai, Teruhiko Koike, Shigeru Kanda, Akira Nakamura, Shosuke Satake, Hiroyuki Umegaki, Akihisa Iguchi, Atorvastatin, 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, reduces bone resorption in the elderly. Journal of the American Geriatrics Society. ,vol. 51, pp. 1677- 1678 ,(2003) , 10.1046/J.1532-5415.2003.515248.X
Ahmed El-Sohemy, Statin Drugs and the Risk of Fracture JAMA. ,vol. 284, pp. 1921- 1922 ,(2000) , 10.1001/JAMA.284.15.1921
Brandon J Orr-Walker, Judith M Clearwater, Anne M Horne, Margaret C Evans, M.A.F Murray, Alan R McNeil, Greg D Gamble, Ian R Reid, Ruth W Ames, Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial The American Journal of Medicine. ,vol. 109, pp. 362- 370 ,(2000) , 10.1016/S0002-9343(00)00510-6
Jose M Mostaza, Concepción De la Piedra, Manuel Dı́az Curiel, Rocı́o Peña, Carlos Lahoz, Pravastatin therapy increases procollagen I N-terminal propeptide (PINP), a marker of bone formation in post-menopausal women. Clinica Chimica Acta. ,vol. 308, pp. 133- 137 ,(2001) , 10.1016/S0009-8981(01)00476-4
K Arnold Chan, Susan E Andrade, Myde Boles, Diana SM Buist, Gary A Chase, James G Donahue, Michael J Goodman, Jerry H Gurwitz, Andrea Z LaCroix, Richard Platt, Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women The Lancet. ,vol. 355, pp. 2185- 2188 ,(2000) , 10.1016/S0140-6736(00)02400-4
Douglas C. Bauer, Greg R. Mundy, Sophie A. Jamal, Dennis M. Black, Jane A. Cauley, Kristine E. Ensrud, Marjolein van der Klift, Huibert A. P. Pols, Use of Statins and Fracture Archives of Internal Medicine. ,vol. 164, pp. 146- 152 ,(2004) , 10.1001/ARCHINTE.164.2.146
Julie A. Pasco, Mark A. Kotowicz, Margaret J. Henry, Kerrie M. Sanders, Geoffrey C. Nicholson, Statin Use, Bone Mineral Density, and Fracture Risk: Geelong Osteoporosis Study JAMA Internal Medicine. ,vol. 162, pp. 537- 540 ,(2002) , 10.1001/ARCHINTE.162.5.537
G Mundy, R Garrett, S Harris, J Chan, D Chen, G Rossini, B Boyce, M Zhao, Gl Gutierrez, Stimulation of Bone Formation in Vitro and in Rodents by Statins Science. ,vol. 286, pp. 1946- 1949 ,(1999) , 10.1126/SCIENCE.286.5446.1946
Bettina A Hamelin, Jacques Turgeon, Hydrophilicity/ lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors Trends in Pharmacological Sciences. ,vol. 19, pp. 26- 37 ,(1998) , 10.1016/S0165-6147(97)01147-4